129 related articles for article (PubMed ID: 37881901)
1. Ertapenem Versus Meropenem for the Treatment of Extended Spectrum Beta-Lactamase-Producing Enterobacterales Bacteremia in Critically Ill Patients.
VanDorf S; Shah P; Yost CN
Ann Pharmacother; 2024 Jul; 58(7):690-697. PubMed ID: 37881901
[TBL] [Abstract][Full Text] [Related]
2. Propensity Score and Desirability of Outcome Ranking Analysis of Ertapenem for Treatment of Nonsevere Bacteremic Urinary Tract Infections Due to Extended-Spectrum-Beta-Lactamase-Producing
Gutiérrez-Gutiérrez B; Pérez-Nadales E; Pérez-Galera S; Fernández-Ruiz M; Carratalà J; Oriol I; Cordero E; Lepe JA; Tan BH; Corbella L; Paul M; Natera AM; David MD; Montejo M; Iyer RN; Pierrotti LC; Merino E; Steinke SM; Rana MM; Muñoz P; Mularoni A; van Delden C; Grossi PA; Seminari EM; Gunseren F; Lease ED; Roilides E; Fortún J; Arslan H; Coussement J; Tufan ZK; Pilmis B; Rizzi M; Loeches B; Eriksson BM; Abdala E; Soldani F; Lowman W; Clemente WT; Bodro M; Fariñas MC; Kazak E; Martínez-Martínez L; Aguado JM; Torre-Cisneros J; Pascual Á; Rodríguez-Baño J;
Antimicrob Agents Chemother; 2021 Oct; 65(11):e0110221. PubMed ID: 34370578
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of de-escalation therapy to ertapenem for treatment of infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae: an open-label randomized controlled trial.
Rattanaumpawan P; Werarak P; Jitmuang A; Kiratisin P; Thamlikitkul V
BMC Infect Dis; 2017 Mar; 17(1):183. PubMed ID: 28249572
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.
Collins VL; Marchaim D; Pogue JM; Moshos J; Bheemreddy S; Sunkara B; Shallal A; Chugh N; Eiseler S; Bhargava P; Blunden C; Lephart PR; Memon BI; Hayakawa K; Abreu-Lanfranco O; Chopra T; Munoz-Price LS; Carmeli Y; Kaye KS
Antimicrob Agents Chemother; 2012 Apr; 56(4):2173-7. PubMed ID: 22290982
[TBL] [Abstract][Full Text] [Related]
5. Clinical characteristics and outcome of critically ill patients with bacteremia caused by extended-spectrum β-lactamase-producing and non-producing Escherichia coli.
Haruki Y; Hagiya H; Haruki M; Sugiyama T
J Infect Chemother; 2018 Nov; 24(11):944-947. PubMed ID: 29803763
[TBL] [Abstract][Full Text] [Related]
6. Thirty-Day Mortality Rates in Patients with Extended-Spectrum β-Lactamase-Producing
Park JJ; Jung EJ; Kim JY; Seo YB; Lee J; Jung Y
Antimicrob Agents Chemother; 2022 Jul; 66(7):e0028722. PubMed ID: 35708330
[TBL] [Abstract][Full Text] [Related]
7. Carbapenem therapy for bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli or Klebsiella pneumoniae: implications of ertapenem susceptibility.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Antimicrob Agents Chemother; 2012 Jun; 56(6):2888-93. PubMed ID: 22430969
[TBL] [Abstract][Full Text] [Related]
8. Should we consider faecal colonisation with extended-spectrum β-lactamase-producing Enterobacteriaceae in empirical therapy of community-onset sepsis?
Stupica D; Lusa L; Klevišar MN; Terzić S; Pirš M; Premru MM; Strle F
Int J Antimicrob Agents; 2017 Oct; 50(4):564-571. PubMed ID: 28711676
[TBL] [Abstract][Full Text] [Related]
9. Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.
Veve MP; Wagner JL; Kenney RM; Grunwald JL; Davis SL
Int J Antimicrob Agents; 2016 Jul; 48(1):56-60. PubMed ID: 27234673
[TBL] [Abstract][Full Text] [Related]
10. Is Carbapenem Therapy Necessary for the Treatment of Non-CTX-M Extended-Spectrum β-Lactamase-Producing Enterobacterales Bloodstream Infections?
Hareza DA; Cosgrove SE; Simner PJ; Harris AD; Bergman Y; Conzemius R; Jacobs E; Beisken S; Tamma PD
Clin Infect Dis; 2024 May; 78(5):1103-1110. PubMed ID: 37972276
[TBL] [Abstract][Full Text] [Related]
11. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
12. Retrospective assessment of antimicrobial stewardship initiative in outpatient use of ertapenem for uncomplicated extended spectrum beta lactamase Enterobacteriaceae urinary tract infections.
Wong CP; Delate T; Hudson E; Nguyen JK; Yang SJ; Abraham M
BMC Infect Dis; 2021 Aug; 21(1):823. PubMed ID: 34399680
[TBL] [Abstract][Full Text] [Related]
13. Non-intravenous carbapenem-sparing antibiotics for definitive treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum β-lactamase (ESBL) or AmpC β-lactamase: A propensity score study.
Meije Y; Pigrau C; Fernández-Hidalgo N; Clemente M; Ortega L; Sanz X; Loureiro-Amigo J; Sierra M; Ayestarán A; Morales-Cartagena A; Ribera A; Duarte A; Abelenda G; Rodríguez-Baño J; Martínez-Montauti J
Int J Antimicrob Agents; 2019 Aug; 54(2):189-196. PubMed ID: 31075401
[TBL] [Abstract][Full Text] [Related]
14. Use of non-carbapenem antibiotics to treat severe extended-spectrum β-lactamase-producing Enterobacteriaceae infections in intensive care unit patients.
Luyt CE; Faure M; Bonnet I; Besset S; Huang F; Junot H; Hékimian G; Schmidt M; Bréchot N; Combes A; Aubry A; Mayaux J; Chastre J
Int J Antimicrob Agents; 2019 May; 53(5):547-552. PubMed ID: 30742956
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of ertapenem vs. other carbapenems for the treatment of extended-spectrum-β-lactamase-producing Enterobacterales infection: A systematic review and meta-analysis.
Huang PY; Hsu CK; Liu TH; Wu JY; Tang HJ; Tsai YW; Lai CC; Chang YH
J Glob Antimicrob Resist; 2023 Jun; 33():201-207. PubMed ID: 36944409
[TBL] [Abstract][Full Text] [Related]
16. Bloodstream infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae at a tertiary care hospital in New Zealand: risk factors and outcomes.
Freeman JT; McBride SJ; Nisbet MS; Gamble GD; Williamson DA; Taylor SL; Holland DJ
Int J Infect Dis; 2012 May; 16(5):e371-4. PubMed ID: 22401750
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem for the treatment of urinary tract infections caused by extended-spectrum β-lactamase-producing bacteria in children.
Dalgic N; Sancar M; Bayraktar B; Dincer E; Pelit S
Scand J Infect Dis; 2011 May; 43(5):339-43. PubMed ID: 21271945
[TBL] [Abstract][Full Text] [Related]
18. [Clinical impact of ertapenem de-escalation in critically-ill patients with Enterobacteriaceae infections].
Cuesta DP; Blanco VM; Vallejo ME; Hernández-Gómez C; Maya JJ; Motoa G; Correa A; Matta L; Rosso F; Camargo RD; Muñoz M; Florez E; Nagles J; Ovalle A; Reyes S; Villegas MV
Rev Chilena Infectol; 2019 Feb; 36(1):9-15. PubMed ID: 31095199
[TBL] [Abstract][Full Text] [Related]
19. Is It Time to Rethink the Notion of Carbapenem-Sparing Therapy Against Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae Bloodstream Infections? A Critical Review.
Chastain DB; White BP; Cretella DA; Bland CM
Ann Pharmacother; 2018 May; 52(5):484-492. PubMed ID: 29239220
[TBL] [Abstract][Full Text] [Related]
20. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
